Navigation Links
Vitamin D, Interferon Alpha Vaccine Show Promise Against Lupus
Date:11/6/2011

By Serena Gordon
HealthDay Reporter

SATURDAY, Nov. 5 (HealthDay News) -- Two experimental treatments take aim at the destructive immune response believed to cause lupus, according to new research presented at the American College of Rheumatology annual meeting.

One study looked at large doses of vitamin D, while the other was a trial of a potential vaccine against an immune system protein called interferon alpha.

"This is an incredibly exciting time in lupus research. The academic and pharmaceutical communities are involved in studies that will hopefully lead to more effective and safer treatments," said Dr. Cynthia Aranow, an investigator at the Feinstein Institute for Medical Research in Manhasset, N.Y. She was not involved in the current studies.

Of these latest studies, Aranow said that both appeared to have an effect on immune system cells, but neither was designed to assess whether or not there was enough of an effect to make a difference to a patient (a clinical response).

Lupus is a chronic autoimmune disease that can affect almost any part of the body, including the skin, joints, kidneys, lungs, nervous system and other organs, according to the Office on Women's Health, part of the U.S. Department of Health and Human Services. An autoimmune disease is one that develops because the immune system mistakenly sees healthy cells in the body as foreign invaders, such as a virus. Instead of fending off bacteria and other invaders as they should, some immune system cells begin attacking healthy cells.

The problem in developing a treatment for lupus and other autoimmune diseases is that a treatment can't just shut down the entire immune system, because that would leave the body too vulnerable to infection. So, researchers have been trying to find the specific immune cells involved in causing lupus. Research has been looking for ways to slow these cells down, or maybe even destroy them without damaging the rest of the immune system.

The first study, scheduled for presentation Nov. 6 at the ACR meeting in Chicago by Dr. Benjamin Terrier of the Pitie-Salpetriere Hospital in Paris, looked at the effect large doses of vitamin D might have on the immune response.

The study included 24 people with lupus who had no or mild disease activity and low levels of vitamin D. At the start of the study, they were given an injection of 100,000 international units of vitamin D once a week for four weeks. After that, they received a once-a-month injection of the same dose of vitamin D for another six months.

The treatment was very well tolerated, and no one developed too much calcium in their blood or calcium deposits (kidney stones), according to the researchers.

The investigators also found that the treatment boosted the activity of good immune cells, and dampened some of those believed to play a role in lupus.

"It's exciting to see that they were able to reverse some of the immunologic dysfunction associated with lupus, but we need a large randomized clinical trial to confirm this," said Aranow.

She added that the dose of vitamin D used in the study was quite large, and it's not something that people with lupus should attempt to duplicate on their own.

The second study involved 28 people with mild to moderate lupus who were given four doses of a vaccine against interferon alpha (IFNa), an immune system protein that's known to play a role in the severity of lupus.

"We were able to demonstrate that the IFNa signature (in excess in lupus patients) can be turned down by vaccinating patients against their own IFNa. The drug is called IFNa-Kinoid. [It's] a modified IFNa, devoid of IFNa biological activity, but modified in such a way that it becomes recognized by the immune system of the patient," explained Dr. Frederic Houssiau, head of rheumatology at the Catholic University of Louvain in Brussels.

He said the patient's immune system then begins to make antibodies against their own INFa.

Houssiau's team, along with colleagues from the manufacturer of the vaccine, Neovacs, found the drug to be well tolerated with no significant side effects.

"This is an early, first step. It appears to be safe. And, the fact that they could show that they could inhibit or down-regulate the interferon signature is very promising," said Aranow.

Houssiau didn't know what the vaccine might cost if developed commercially, but said it would likely be more expensive than the standard therapies currently used.

For people living with lupus, he added, "there is hope. By unraveling more and more pathways at work in lupus patients, we are now able to develop new, much more targeted drugs to tackle the disease."

Because this research was presented at a medical meeting, the data and conclusions should be viewed as preliminary until published in a peer-reviewed journal.

More information

Learn more about lupus at WomensHealth.gov.

SOURCES: Frederic Houssiau, M.D., Ph.D., head of rheumatology and professor of rheumatology, Catholic University of Louvain, Brussels, Belgium; Cynthia Aranow, M.D., investigator, Feinstein Institute for Medical Research, Manhasset, N.Y.; American College of Rheumatology, news release, Nov. 5, 2011; presentations, American College of Rheumatology annual meeting, Chicago


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Vitamin D Lacking in Many Spine Surgery Patients
2. Low vitamin D levels do not increase the risk of chronic obstructive pulmonary disease
3. Caucasians who avoid sun exposure more likely to be vitamin D deficient, Stanford study suggests
4. Low vitamin D common in spine surgery patients
5. Vitamin B-based treatment for corneal disease may offer some patients a permanent solution
6. Women do not get enough vitamin D during the menopause
7. Research Sheds Light on Vitamin Ds Role in Immunity
8. Extra Vitamin E May Be Associated With Prostate Cancer
9. National study finds vitamin E supplement may increase prostate cancer risk
10. Oral steroids linked to severe vitamin D deficiency in nationwide study
11. Could Too Little Vitamin B-12 Shrink the Aging Brain?
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
 Vitamin D, Interferon Alpha Vaccine Show Promise Against Lupus
(Date:10/12/2017)... , ... October 12, 2017 , ... ... to meet the demand of today’s consumer and regulatory authorities worldwide. From Children’s ... experts and tested to meet the highest standard. , These products are ...
(Date:10/12/2017)... ... October 12, 2017 , ... Asante, a nationally ... care, have expanded their existing home health joint venture through an agreement, effective ... operating a joint venture home health company with Asante, delivering clinically integrated care, ...
(Date:10/12/2017)... ... October 12, 2017 , ... HMP , a leader ... a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare Website.’ Winners were ... 11, 2017. , The annual award competition recognizes editorial and design excellence across a ...
(Date:10/12/2017)... ... 12, 2017 , ... Women-owned and Grand Rapids-based workplace wellness ... in Wellness® by Best and Brightest. OnSite Wellness will be honored at the ... 7:30 a.m. to 2 p.m. at the Henry Autograph Collection Hotel, located at ...
(Date:10/12/2017)... ... October 12, 2017 , ... Vohra Chief Medical Officer ... physician colleagues, skilled nursing facility medical directors and other clinicians at various events ... Care." , "At many of these conferences we get to educate other physicians, ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... , Oct. 4, 2017  South Korean-based healthcare ... CPR training aide "cprCUBE" on Kickstarter. The device will ... during cardiac arrests with better efficiency compared to the ... offers real-time feedback on efficacy of the compression for ... campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... Oct. 2, 2017  Eli Lilly and Company (NYSE: ... for the third quarter of 2017 on Tuesday, October ... on that day with the investment community and media ... The conference call will begin at 9 a.m. Eastern ... a live webcast of the conference call through a ...
(Date:9/28/2017)... -- Hill-Rom Holdings, Inc. (NYSE: HRC), will host its ... on Friday, November 3, 2017, beginning at 7:00 a.m. ... 8:30 a.m. (CDT) / 9:30 a.m. (EDT). ... and guidance for 2018, Hill-Rom executives will also highlight ... and long-range financial outlook through 2020. ...
Breaking Medicine Technology: